Cargando…

Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation

Validating an exposure pathway model is difficult because the biomarker, which is often used to evaluate the model prediction, is an integrated measure for exposures from all the exposure routes and pathways. The purpose of this article is to demonstrate a method to use pharmacokinetic (PK) modeling...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Ye, Akland, Gerry G., Pellizzari, Edo D., Berry, Maurice R., Melnyk, Lisa Jo
Formato: Texto
Lenguaje:English
Publicado: National Institute of Environmental Health Science 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1253662/
https://www.ncbi.nlm.nih.gov/pubmed/15579416
http://dx.doi.org/10.1289/ehp.6367
_version_ 1782125751259103232
author Hu, Ye
Akland, Gerry G.
Pellizzari, Edo D.
Berry, Maurice R.
Melnyk, Lisa Jo
author_facet Hu, Ye
Akland, Gerry G.
Pellizzari, Edo D.
Berry, Maurice R.
Melnyk, Lisa Jo
author_sort Hu, Ye
collection PubMed
description Validating an exposure pathway model is difficult because the biomarker, which is often used to evaluate the model prediction, is an integrated measure for exposures from all the exposure routes and pathways. The purpose of this article is to demonstrate a method to use pharmacokinetic (PK) modeling and computer simulation to guide the design of field studies to validate pathway models. The children’s dietary intake model is discussed in detail as an example. Three important aspects are identified for a successful design to evaluate the children’s dietary intake model: a) longitudinally designed study with significant changes in the exposure for the route/pathway of interest, b) short biologic half-life of the selected chemical, and c) surface loading of the selected chemical at sufficient levels. Using PK modeling to guide a study design allowed a path-specific exposure model to be evaluated using urinary metabolite biomarkers.
format Text
id pubmed-1253662
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher National Institute of Environmental Health Science
record_format MEDLINE/PubMed
spelling pubmed-12536622005-11-08 Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation Hu, Ye Akland, Gerry G. Pellizzari, Edo D. Berry, Maurice R. Melnyk, Lisa Jo Environ Health Perspect Research Validating an exposure pathway model is difficult because the biomarker, which is often used to evaluate the model prediction, is an integrated measure for exposures from all the exposure routes and pathways. The purpose of this article is to demonstrate a method to use pharmacokinetic (PK) modeling and computer simulation to guide the design of field studies to validate pathway models. The children’s dietary intake model is discussed in detail as an example. Three important aspects are identified for a successful design to evaluate the children’s dietary intake model: a) longitudinally designed study with significant changes in the exposure for the route/pathway of interest, b) short biologic half-life of the selected chemical, and c) surface loading of the selected chemical at sufficient levels. Using PK modeling to guide a study design allowed a path-specific exposure model to be evaluated using urinary metabolite biomarkers. National Institute of Environmental Health Science 2004-12 2004-08-16 /pmc/articles/PMC1253662/ /pubmed/15579416 http://dx.doi.org/10.1289/ehp.6367 Text en http://creativecommons.org/publicdomain/mark/1.0/ Publication of EHP lies in the public domain and is therefore without copyright. All text from EHP may be reprinted freely. Use of materials published in EHP should be acknowledged (for example, ?Reproduced with permission from Environmental Health Perspectives?); pertinent reference information should be provided for the article from which the material was reproduced. Articles from EHP, especially the News section, may contain photographs or illustrations copyrighted by other commercial organizations or individuals that may not be used without obtaining prior approval from the holder of the copyright.
spellingShingle Research
Hu, Ye
Akland, Gerry G.
Pellizzari, Edo D.
Berry, Maurice R.
Melnyk, Lisa Jo
Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation
title Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation
title_full Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation
title_fullStr Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation
title_full_unstemmed Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation
title_short Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation
title_sort use of pharmacokinetic modeling to design studies for pathway-specific exposure model evaluation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1253662/
https://www.ncbi.nlm.nih.gov/pubmed/15579416
http://dx.doi.org/10.1289/ehp.6367
work_keys_str_mv AT huye useofpharmacokineticmodelingtodesignstudiesforpathwayspecificexposuremodelevaluation
AT aklandgerryg useofpharmacokineticmodelingtodesignstudiesforpathwayspecificexposuremodelevaluation
AT pellizzariedod useofpharmacokineticmodelingtodesignstudiesforpathwayspecificexposuremodelevaluation
AT berrymauricer useofpharmacokineticmodelingtodesignstudiesforpathwayspecificexposuremodelevaluation
AT melnyklisajo useofpharmacokineticmodelingtodesignstudiesforpathwayspecificexposuremodelevaluation